The company collects entire stool samples along with rich metadata to build a unique dataset that enables personalized medicine by bringing rich context to the samples. They collect data on 6 of the top 7 indicators of microbiome diversity and health, and have developed the BioFlux™ Metabolomic Model for in silico product development or existing product/drug/chemical impact testing on the metabolic output of the microbiome. The company targets the "most wanted" microbes for isolation and culture, currently curating a collection of bespoke microbes from diverse sources, including the deep sea. They also develop formulas with their AI model, BioFlux Metabolic Model, to rationally design products that target functions such as glucose/fructose metabolism, cardiovascular health, and sleep. The company's goal is to enable medical researchers to receive assistance for microbiome research that could result in big discoveries for a future of precision medicine.